|
CN108697686A
|
|
Composition and its method
|
|
AU2014269996A1
|
|
A method of managing Hepatic Fibrosis, Hepatitis C Virus and associated condition
|
|
EP2981259A1
|
|
A composition for treating neuropathy, a process and a method of treatment thereof
|
|
US2015283126A1
|
|
Method of managing urolithiasis and related urological disorders
|
|
CN104582699A
|
|
A method of managing diabetic foot ulcers, pressure ulcers, venous leg ulcers and associated complication
|
|
TW201309289A
|
|
A method of managing broncho-constrictive condition
|
|
RU2532357C2
|
|
Method of therapy of bronchoconstrictive conditions
|
|
AU2011369800A1
|
|
A method of managing hypercortisolemia, headache disorders, neuropathic pain and related disorders
|
|
CN103459362A
|
|
A complex of garcinol, cyclodextrin and method thereof
|
|
TW201219048A
|
|
A novel standardized composition, method of manufacture and use in the resolution of rna virus infection
|
|
AU2010354973A1
|
|
A method for preparation of highly pure asiaticoside composition from Centella asiatica and a method of use thereof
|
|
AU2009347566A1
|
|
A novel standardized composition, method of manufacture and use in the resolution of RNA virus infection
|
|
EP2445488A1
|
|
Process for obtaining purified pterostilbene and methods of use thereof
|
|
CN102015746A
|
|
Compositions comprising galactomannan and a process thereof
|
|
CN101657194A
|
|
Pharmaceutical compositions comprising trigonelline and 4-hydroxyisoleucine and process thereof
|
|
US2008199517A1
|
|
Composition and a process thereof
|
|
AU2008215743A1
|
|
A composition for selective serotonin reuptake inhibition and process thereof
|
|
KR20060090272A
|
|
A process for isolating, purifying and formulating a stable, commercial grade lutein paste from oleoresin
|
